<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38535608</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>Beau's Lines and COVID-19; A Systematic Review on Their Association.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">265</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens13030265</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Beau's lines are transverse grooves in the nail plate that result from transient interruption of the growth of the proximal nail matrix after severe disease. The aim of this study is to systematically report all evidence on the association of Beau's lines with COVID-19 infection or vaccination against COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed and Scopus databases were searched up to January 2024 for articles reporting Beau's lines associated with COVID-19 infection or vaccination for COVID-19.</AbstractText><AbstractText Label="PROSPERO ID" NlmCategory="UNASSIGNED">CRD42024496830.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PubMed search identified 299 records while Scopus search identified 18 records. After screening the bibliography, nine studies including 35 cases were included in our systematic review. The studies were reported from different areas around the world. Included studies documented Beau's lines following COVID-19 vaccination (two studies) or after COVID-19 infection (seven studies). High variability was recorded in onset and resolution times among included cases, averaging 3 months and 6 months after COVID-19 infection, respectively. In the two studies reporting Beau's lines after vaccination, onset was at 7 days and 6 weeks and resolution occurred after 8 and 17 weeks, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To the best of our knowledge, this is the first systematic review reporting the association of Beau's lines with COVID-19 infection and vaccination. Severe immune response can result in the formation of these nail disorders. Of importance, Beau's lines represent a potential indicator of prior severe COVID-19 infection or vaccination for COVID-19, as well as a sign of long COVID-19 syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agouridis</LastName><ForeName>Aris P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-9749-5075</Identifier><AffiliationInfo><Affiliation>School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, German Oncology Center, 4108 Limassol, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastori-Kourmpani</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antoniou</LastName><ForeName>Polyna</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantinou</LastName><ForeName>Paschalis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizos</LastName><ForeName>Evangelos C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Nursing, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsioutis</LastName><ForeName>Constantinos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7865-8529</Identifier><AffiliationInfo><Affiliation>School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Beau&#x2019;s lines</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">nails</Keyword><Keyword MajorTopicYN="N">skin</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38535608</ArticleId><ArticleId IdType="pmc">PMC10974365</ArticleId><ArticleId IdType="doi">10.3390/pathogens13030265</ArticleId><ArticleId IdType="pii">pathogens13030265</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Coronavirus Disease (COVID-19) Outbreak.  [(accessed on 5 January 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061&#x2013;1069. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Galv&#xe1;n Casas C., Catal&#xe0; A., Carretero Hern&#xe1;ndez G., Rodr&#xed;guez-Jim&#xe9;nez P., Fern&#xe1;ndez-Nieto D., Rodr&#xed;guez-Villa Lario A., Navarro Fern&#xe1;ndez I., Ruiz-Villaverde R., Falkenhain-L&#xf3;pez D., Llamas Velasco M., et al. Classification of the cutaneous manifestations of COVID-19: A rapid prospective nationwide consensus study in Spain with 375 cases. Br. J. Dermatol. 2020;183:71&#x2013;77. doi: 10.1111/bjd.19163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19163</ArticleId><ArticleId IdType="pmc">PMC7267236</ArticleId><ArticleId IdType="pubmed">32348545</ArticleId></ArticleIdList></Reference><Reference><Citation>Preda-Naumescu A., Penney K., Pearlman R.L., Brodell R.T., Daniel C.R., Nahar V.K. Nail Manifestations in COVID-19: Insight into a Systemic Viral Disease. Skin. Appendage Disord. 2021;183:433&#x2013;438. doi: 10.1159/000518087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518087</ArticleId><ArticleId IdType="pmc">PMC8450840</ArticleId><ArticleId IdType="pubmed">34580633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollina U., Kanitakis J., Baran R. Nails and COVID-19&#x2014;A comprehensive review of clinical findings and treatment. Dermatol. Ther. 2021;34:e15100. doi: 10.1111/dth.15100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15100</ArticleId><ArticleId IdType="pmc">PMC8420555</ArticleId><ArticleId IdType="pubmed">34398500</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadeler E., Morrison B.W., Tosti A. A review of nail findings associated with COVID-19 infection. J. Eur. Acad. Dermatol. Venereol. 2021;35:e699&#x2013;e709. doi: 10.1111/jdv.17448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17448</ArticleId><ArticleId IdType="pmc">PMC8447455</ArticleId><ArticleId IdType="pubmed">34131957</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Li K. Images in clinical medicine. Multiple Beau&#x2019;s lines. N. Engl. J. Med. 2010;362:e63. doi: 10.1056/NEJMicm0906698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMicm0906698</ArticleId><ArticleId IdType="pubmed">20484394</ArticleId></ArticleIdList></Reference><Reference><Citation>Agouridis A.P., Ntzani E.E., Anastasiou G., Barkas F., Rizos E.C. Unravelling Beau&#x2019;s Lines as a Potential Indicator of Severe Immune Response in Covid-19 and Reinfection. Eur. J. Case Rep. Intern. Med. 2024;11:004281. doi: 10.12890/2024_004281.</Citation><ArticleIdList><ArticleId IdType="doi">10.12890/2024_004281</ArticleId><ArticleId IdType="pmc">PMC10860917</ArticleId><ArticleId IdType="pubmed">38352813</ArticleId></ArticleIdList></Reference><Reference><Citation>Moola S., Munn Z., Tufanaru C., Aromataris E., Sears K., Sfetcu R., Currie M., Qureshi R., Mattis P., Lisy K.M., et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E., Munn Z., editors. Joanna Briggs Institute Reviewer&#x2019;s Manual. The Joanna Briggs Institute; Adelaide, Australia: 2017.</Citation></Reference><Reference><Citation>Wells G.A., Shea B., O&#x2019;Connell D., Peterson J., Welch, Losos M., Tugwell P., Ga S.W., Zello G. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014.  [(accessed on 5 January 2024)].  Available online:  https://api.semanticscholar.org/CorpusID:79550924.</Citation></Reference><Reference><Citation>Lo C.K., Mertz D., Loeb M. Newcastle-Ottawa Scale: Comparing reviewers&#x2019; to authors&#x2019; assessments. BMC Med. Res. Methodol. 2014;14:45. doi: 10.1186/1471-2288-14-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-45</ArticleId><ArticleId IdType="pmc">PMC4021422</ArticleId><ArticleId IdType="pubmed">24690082</ArticleId></ArticleIdList></Reference><Reference><Citation>Alobaida S., Lam J.M. Beau lines associated with COVID-19. Cmaj. 2020;192:E1040. doi: 10.1503/cmaj.201619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.201619</ArticleId><ArticleId IdType="pmc">PMC7504889</ArticleId><ArticleId IdType="pubmed">32900765</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ide S., Morioka S., Inada M., Ohmagari N. Beau&#x2019;s Lines and Leukonychia in a COVID-19 Patient. Intern. Med. 2020;59:3259. doi: 10.2169/internalmedicine.6112-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.6112-20</ArticleId><ArticleId IdType="pmc">PMC7807123</ArticleId><ArticleId IdType="pubmed">33132338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf G.K., French L.E. Beau-Lines of the fingernails in association with pediatric SARS-CoV-2 infections. J. Dtsch. Dermatol. Ges. 2021;19:744&#x2013;745. doi: 10.1111/ddg.14350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ddg.14350</ArticleId><ArticleId IdType="pmc">PMC8251186</ArticleId><ArticleId IdType="pubmed">33768703</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Ngo T., Zhu T.H., Halverstam C. Telogen effluvium, Beau lines, and acral peeling associated with COVID-19 infection. JAAD Case Rep. 2021;13:138&#x2013;140. doi: 10.1016/j.jdcr.2021.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.05.026</ArticleId><ArticleId IdType="pmc">PMC8180346</ArticleId><ArticleId IdType="pubmed">34124324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricardo J.W., Lipner S.R. Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Rep. 2021;17:18&#x2013;20. doi: 10.1016/j.jdcr.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8480201</ArticleId><ArticleId IdType="pubmed">34611542</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula J.A., Franck C.L., Justino S.R., Leite L.S., Ramos Junior O., Rabito E.I. Beau&#x2019;s line in COVID-19 after a long ICU stay. Nutr. Hosp. 2022;39:945&#x2013;948. doi: 10.20960/nh.04131.</Citation><ArticleIdList><ArticleId IdType="doi">10.20960/nh.04131</ArticleId><ArticleId IdType="pubmed">35815764</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam K., Yim E. Transverse Leukonychia and Beau Lines Following COVID-19 Vaccination. Cutis. 2022;110:E28&#x2013;E31. doi: 10.12788/cutis.0606.</Citation><ArticleIdList><ArticleId IdType="doi">10.12788/cutis.0606</ArticleId><ArticleId IdType="pubmed">36219636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutlu O., Demircan Y.T., Yildiz K., Kalkan G., Demirseren D.D., An I., Oba M.C., Emre S., Senel E., Bilgili S.G., et al. The effect of COVID-19 on development of hair and nail disorders: A Turkish multicenter, controlled study. Int. J. Dermatol. 2023;62:202&#x2013;211. doi: 10.1111/ijd.16454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijd.16454</ArticleId><ArticleId IdType="pmc">PMC9874876</ArticleId><ArticleId IdType="pubmed">36281828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.R., Yu D.A., Lee S.R., Lim S.S., Mun J.H. Beau&#x2019;s Lines and Onychomadesis: A Systematic Review of Characteristics and Aetiology. Acta Derm.-Venereol. 2023;103:adv18251. doi: 10.2340/actadv.v103.18251.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/actadv.v103.18251</ArticleId><ArticleId IdType="pmc">PMC10626449</ArticleId><ArticleId IdType="pubmed">37902467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwar A.J., De D., Narang T. Beau lines in an infant--are they so uncommon? Pediatr Dermatol. 2007;24:581&#x2013;582. doi: 10.1111/j.1525-1470.2007.00535.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1470.2007.00535.x</ArticleId><ArticleId IdType="pubmed">17958826</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Bunker C.B., Ciurtin C., Porter J.C., Chambers R.C., Papdopoulou C., Garthwaite H., Hillman T., Heightman M., Howell K.J., et al. Chilblain-like acral lesions in long COVID-19: Management and implications for understanding microangiopathy. Lancet Infect Dis. 2021;21:912. doi: 10.1016/S1473-3099(21)00133-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00133-X</ArticleId><ArticleId IdType="pmc">PMC8221732</ArticleId><ArticleId IdType="pubmed">33705725</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Whettlock E.M., Liu S., Arachchillage D.J., Boyton R.J. The immunology of long COVID. Nat. Rev. Immunol. 2023;23:618&#x2013;634. doi: 10.1038/s41577-023-00904-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaias N. The Nail in Health and Disease. Springer; Dordrecht, The Netherlands: 1980. Anatomy and Physiology; pp. 1&#x2013;18.</Citation></Reference><Reference><Citation>Tsioutis C., Tofarides A., Spernovasilis N. Transition beyond the acute phase of the COVID-19 pandemic: Need to address the long-term health impacts of COVID-19. World J. Clin. Cases. 2022;10:9967&#x2013;9969. doi: 10.12998/wjcc.v10.i27.9967.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v10.i27.9967</ArticleId><ArticleId IdType="pmc">PMC9516898</ArticleId><ArticleId IdType="pubmed">36186173</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Sivan M., Delaney B., Evans R., Milne R. Long covid-an update for primary care. Bmj. 2022;378:e072117. doi: 10.1136/bmj-2022-072117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072117</ArticleId><ArticleId IdType="pubmed">36137612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>